# IntelliCyt Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/intellicyt

- Industry: Biotechnology
- Headquarters: Albuquerque, US
- Website: www.intellicyt.com
- Total disclosed funding: $9.5M
- Latest round: Series C (Apr 25, 2013)
- Investors on record: 5

## About

IntelliCyt Corporation specializes in high-throughput screening technologies, providing innovative solutions for cell-based assays to accelerate scientific discovery.Founded in 2006 and headquartered in Albuquerque, US, IntelliCyt Corporation focuses on developing advanced technologies for cell analysis. The company was acquired by Sartorius in June 2016 for USD 90 mn. Prior to the acquisition, IntelliCyt had completed 8 deals, showcasing its growth in the industry.IntelliCyt offers advanced high-throughput screening (HTS) solutions through its iQue® HTS platforms, which enable rapid analysis of cell-based assays. Key products include the iQue® 5 and iQue® 3 cytometers, designed for workflows such as antibody discovery and immuno-oncology studies. The platforms leverage sophisticated flow cytometry technology and user-friendly software, iQue Forecyt®, enhancing both assay development and data visualization. The company's clientele includes various academic, biotech, and pharmaceutical organizations across North America, Europe, and Asia.IntelliCyt generates revenue predominantly through direct sales of its iQue® HTS instruments along with associated reagents and software solutions. The business model is largely B2B, involving clients who purchase equipment and consumables through contractual agreements that may include service packages. This leads to recurring revenue from proprietary reagents validated for use with the iQue® HTS platform, sustained by partnerships with academic and research institutions.With the recent acquisition by Sartorius, IntelliCyt is expected to enhance its product offerings and market reach. The company plans to leverage the funding from the acquisition to develop new products and expand into additional geographic regions, targeting markets in Europe and Asia by 2022. This strategy aims to capitalize on the growing demand for high-throughput screening technologies.

## Funding rounds

- Series C, Apr 25, 2013, $8.4M — Verge, New Mexico Community Capital, Arboretum Ventures, Prolog Ventures
- Seed, Mar 1, 2007, $1.1M — Village Ventures, Verge

## Investors

- Village Ventures (https://capitalatlas.ai/funds/village-ventures) — Seed
- Verge (https://capitalatlas.ai/funds/verge) — Seed, Series C
- New Mexico Community Capital (https://capitalatlas.ai/funds/new-mexico-community-capital) — Series C
- Arboretum Ventures (https://capitalatlas.ai/funds/arboretum-ventures) — Series C
- Prolog Ventures (https://capitalatlas.ai/funds/prolog-ventures) — Series C